Clinical Study

MRI for Assessing Response to Neoadjuvant Therapy in Locally Advanced Rectal Cancer Using DCE-MR and DW-MR Data Sets: A Preliminary Report

Mario Petrillo, 1 Roberta Fusco, 1 Orlando Catalano, 1 Mario Sansone, 2 Antonio Avallone, 3 Paolo Delrio, 4 Biagio Pecori, 5 Fabiana Tatangelo, 6 and Antonella Petrillo 1

1 Division of Radiology, Department of Diagnostic Imaging, Radiant and Metabolic Therapy, Istituto Nazionale Tumori-IRCCS “Fondazione Giovanni Pascale”, Via Mariano Semmola, 80131 Naples, Italy
2 Department of Electrical Engineering and Information Technologies, University of Naples Federico II, Via Claudio 21, 80125 Naples, Italy
3 Division of Gastrointestinal Medical Oncology, Department of Abdominal Oncology, Istituto Nazionale Tumori-IRCCS “Fondazione Giovanni Pascale”, Via Mariano Semmola, 80131 Naples, Italy
4 Division of Gastrointestinal Surgical Oncology, Department of Abdominal Oncology, Istituto Nazionale Tumori-IRCCS “Fondazione Giovanni Pascale”, Via Mariano Semmola, 80131 Naples, Italy
5 Division of Radiotherapy, Department of Diagnostic Imaging, Radiant and Metabolic Therapy, Istituto Nazionale Tumori-IRCCS “Fondazione Giovanni Pascale”, Via Mariano Semmola, 80131 Naples, Italy
6 Division of Diagnostic Pathology, Department of Diagnostic and Laboratory Pathology, Istituto Nazionale Tumori-IRCCS “Fondazione Giovanni Pascale”, Via Mariano Semmola, 80131 Naples, Italy

Correspondence should be addressed to Antonella Petrillo; a.petrillo@istitutotumori.na.it

Received 9 July 2014; Revised 8 May 2015; Accepted 13 May 2015

Academic Editor: Zhengchao Dong

Copyright © 2015 Mario Petrillo et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

To evaluate MRI for neoadjuvant therapy response assessment in locally advanced rectal cancer (LARC) using dynamic contrast enhanced-MRI (DCE-MRI) and diffusion weighted imaging (DWI), we have compared magnetic resonance volumetry based on DCE-MRI (\(V(DCE)\)) and on DWI (\(V(DWI)\)) scans with conventional T2-weighted volumetry (\(V(C)\)) in LARC patients after neoadjuvant therapy. Twenty-nine patients with LARC underwent MR examination before and after neoadjuvant therapy. A manual segmentation was performed on DCE-MR postcontrast images, on DWI (\(b\)-value 800 s/mm\(^2\)), and on conventional T2-weighted images by two radiologists. DCE-MRI, DWI, and T2-weighted volumetric changes before and after treatment were evaluated. Nonparametric sample tests, interobserver agreement, and receiver operating characteristic curve (ROC) were performed. Diagnostic performance linked to DCE-MRI volumetric change was superior to T2-w and DW-MRI volumetric changes performance (specificity 86%, sensitivity 93%, and accuracy 93%). Area Under ROC (AUC) of \(V(DCE)\) was greater than AUCs of \(V(C)\) and \(V(DWI)\) resulting in an increase of 15.6% and 11.1%, respectively. Interobserver agreement between two radiologists was 0.977, 0.864, and 0.756 for \(V(C)\), \(V(DCE)\), and \(V(DWI)\), respectively. \(V(DCE)\) seems to be a promising tool for therapy response assessment in LARC. Further studies on large series of patients are needed to refine technique and evaluate its potential value.

1. Introduction

Rectal cancer is a frequent malignancy in both men and women, accounting for 40.290 new cases in the USA in 2012 [1]. Despite the efforts done to introduce screening programs, most patients are diagnosed in a locally advanced stage of the disease (T3-T4, Nx, and Mx). Total mesorectal excision (TME) combined with preoperative radiation therapy and concurrent chemotherapy (pCRT) is the current standard for locally advanced rectal cancer (LARC) [2]. TME is associated with significant morbidity and functional complications, evolving conservative treatment strategies are being developed for patients with early rectal cancer at diagnosis and patients with significant/complete tumor regression after
A further conservative strategy has been to adopt a “wait and see” policy, omitting surgery when a complete clinical response is obtained after pCRT. This strategy has the advantage of reducing morbidity and provides a “true” organ-sparing approach, considering that sphincter preservation without adequate function has questionable benefit. CRT induces tumor downstaging and complete or partial organ-sparing approach, considering that sphincter preservation without adequate function has questionable benefit. CRT induces tumor downstaging and complete or partial organ-sparing approach, considering that sphincter preservation without adequate function has questionable benefit. CRT induces tumor downstaging and complete or partial organ-sparing approach, considering that sphincter preservation without adequate function has questionable benefit. Thus, patients with clinical T4, nodal involvement, or T3 N0 with a tumor location of ≤ 5 cm from the anal verge, or a circumferential resection margin of ≤ 5 mm, defined by MRI. Exclusion criteria were inability to give informed consent, previous rectal surgery, and contraindications to MRI or to MR contrast media. All patients were enrolled within the phase I-II prospective trial described in [10] which was approved by the Independent Ethical Committee of our institution. They all gave written informed consent to participate in the trial.

2. Materials and Methods

2.1. Patient Selection. Twenty-nine consecutive patients with a median age of 62 years (range 29–76 years) were enrolled in this prospective study, from March 2010 to November 2013. All patients had a biopsy-proven rectal adenocarcinoma. Endorectal ultrasonography, MRI of the liver and pelvis, CT of the abdomen and pelvis, and chest X-ray were used as staging procedures. Inclusion criteria were patients with clinical T4, nodal involvement, or T3 N0 with a tumor location of ≤ 5 cm from the anal verge, or a circumferential resection margin of ≤ 5 mm, defined by MRI. Exclusion criteria were inability to give informed consent, previous rectal surgery, and contraindications to MRI or to MR contrast media. All patients were enrolled within the phase I-II prospective trial described in [10] which was approved by the Independent Ethical Committee of our institution. They all gave written informed consent to participate in the trial.

2.2. Neoadjuvant Therapy. External radiation therapy was performed using a 3-field technique (one posteroanterior and two lateral fields). Standard fractions of 1.8 Gy/day to the reference point were given, 5 times a week up to a total dose of 45 Gy. All patients received biweekly bevacizumab at 5 mg/kg plus three biweekly cycles of oxaliplatin at 100 mg/m² and raltitrexed at 2.5 mg/m², on day 1, and levo-folinic acid at 250 mg/m², and 5-Fluorouracil at 800 mg/m² on day 2 [2, 10].

2.3. MRI Data Acquisitions. All patients underwent DCE-MRI examination before and after pCRT (90 days on average, range 86–94 days between the two MRI evaluations). Imaging was performed with a 1.5 T scanner (Magnetom Symphony, Siemens Medical System, Erlangen, Germany) equipped with a phased-array body coil. Patients were placed in a supine, head-first position. Mild rectal lumen distension was achieved with 60–90 mL of nondiluted ferumoxil (Lumirem, Guerbet, RoissyCdgCedex, France) suspension introduced per rectum [11]. Precontrast coronal T1w 2D turbo spin-echo images and sagittal and axial T2w 2D turbo spin-echo images of the pelvis were obtained. After that, axial DWIs were acquired (spin-echo diffusion-weighted echo-planar imaging [SE-DW-EPI]) at three b-values of 0, 400, and 800 sec/mm². Subsequently, axial, dynamic, contrast-enhanced T1w, FLASH 3D gradient-echo images were acquired. We obtained one sequence before and ten sequences, without any delay, after IV injection of 2 mL/kg of a positive, gadolinium-based paramagnetic contrast medium (Gd-DOTA, Dotarem, Guerbet, RoissyCdgCedex, France). The contrast medium was injected using Spectris Solaris EP MR (MEDRAD Inc., Indianola, PA), with a flow rate of 2 mL/s, followed by a 10 mL saline flush at the same rate. Temporal resolution was 0.58 minutes, corresponding to 35 seconds (as reported in Table 1). Total acquisition time for precontrast and ten postcontrast sequences was 6.4 minutes. Then, sagittal, axial, and coronal postcontrast T1w 2D turbo spin-echo images,
DCE-MRI derived images were obtained by subtracting the basal and postcontrastographic series obtained on DCE-MRI derived images obtained subtracting the basal and postcontrastographic series. The readers calculated tumor volumes specific expertise reading pelvic MR images. The observers independently analyzed by two radiologists with years of experience reading pelvic MR images and pathology reports. There were no differences in the tumor volume (TV); and (c) the tumor volume reduction ratio (Δ volume), which was calculated as follows: (TV pre - TV post) × 100/TV pre, where TV pre is pre-CRT tumor volume and TV post is post-CRT tumor volume.

### 2.4. Image Data Analysis.

The MR images were evaluated on a picture archiving and communication system and were independently analyzed by two radiologists with years of specific expertise reading pelvic MR images. The observers were blinded to each other’s results, the clinical patient data, and pathology reports. The readers calculated tumor volumes by manually tracing the tumor boundaries slice by slice on DCE-MRI derived images obtained subtracting the basal and postcontrastographic series (V(DCE)), on diffusion weighted image a b-value of 800 s/mm² (V(DWI)) and on conventional T2-weighted images (V(C)).

Whole-tumor volume was then calculated considering the total number of pixel (slice by slice) and multiplying this by pixel size in mm². On the T2-weighted images, tumor was defined as areas of isointense signal as compared with the relatively lower hypointense signal of the normal adjacent muscular rectal wall. On post-CRT T2-weighted MR images, areas of markedly low SI at the location of the primary tumor bed were interpreted as fibrosis. As the risk for residual tumor in these fibrotic areas is known to be ±50%, they were also included in the volumetric measurements [12]. On DCE-MRI data sets, measurements were performed on subtraction images considering basal signal and 5th postcontrastographic series. Area of hyper-intense signal compared with normal bowel wall or background of lower SI tissue, were considered as tumor. On the DW images, measurements were performed on high b value (800 sec/mm²) images and were based on a visual analysis. To avoid errors due to T2 shine effect only areas with high SI on high-b value images and low SI on ADC maps, when compared with the normal bowel wall or background of lower SI tissue on high-b value images, were considered tumor.

For each data sets (DCE, DWI, and T2-weighted), the readers determined (a) pre-CRT tumor volume; (b) post-CRT tumor volume; and (c) the tumor volume reduction ratio (Δ volume), which was calculated as follows: (TV pre - TV post) × 100/TV pre, where TV pre is pre-CRT tumor volume and TV post is post-CRT tumor volume.

### 2.5. Surgical Approach and Evaluation of Pathologic Response.

All patients underwent total mesorectal excision after completing pCRT. An anterior resection or an abdominoperineal resection was performed on the basis of the results of post-CRT restaging. The surgical specimens containing the tumor were processed and evaluated by a single pathologist who was not aware of the clinical and MRI findings. Specimens were examined according to the Sixth American Joint Committee on Cancer TNM staging system. The tumor regression grade (TRG) was evaluated according to the method of Mandard et al. [13, 14]. TRG 1 means a complete response with absence of residual cancer and fibrosis extending through the wall. TRG 2 is the presence of residual cancer cells scattered through the fibrosis. TRG 3 corresponds to the presence of fibrosis and tumor cells, with predominance of fibrosis. TRG 4 indicates as fibrosis and tumor cells, with predominance of tumor cells. TRG 5 is the absence of regressive changes. Patients with a TRG 1 or 2 score were considered as responders, whereas the remaining patients (TRG 3, 4, or 5) were classified as not responders [9].

### 2.6. Statistical Analysis.

Tumor volume percentage changes of the responder and nonresponder groups were analyzed using the Mann-Whitney test. A Wilcoxon signed-rank test was used to compare pre- and post-CRT volumes. Receiver Operating Characteristic (ROC) curves were also used to compare the diagnostic performance of V(DCE), V(DWI) and V(C) reduction rates after pCRT. Area Under ROC Curve (AUC) were calculated [15] and optimal thresholds were obtained maximizing the Youden index [16]. Sensitivity, specificity, positive predictive value and negative predictive value were performed considering optimal cut-off values. Fischer exact tests were used to investigate if results were statistically significant. Interobserver agreement was also obtained using interobserver correlation coefficient (ICC) for continuous variables (0–0.20, poor agreement; 0.21–0.40, fair agreement; 0.41–0.60, moderate agreement; 0.61–0.80, good agreement; and 0.81–1.00, excellent agreement).

### Table 1: Pulse sequence parameters on MR studies.

| Sequence       | Orientation | TR/TE/FA (ms/ms/deg.) | AT (min) | FOV (mm × mm) | Acquisition matrix | ST/Gap (mm/mm) | TF |
|----------------|-------------|------------------------|----------|---------------|-------------------|---------------|----|
| T1w 2D TSE     | Coronal     | 499/13/150             | 2.36     | 450 × 450     | 256 × 230         | 3/0           | 3  |
| T2w 2D TSE     | Sagittal    | 4820/98/150            | 4.17     | 260 × 236     | 256 × 139         | 3/0           | 13 |
| T2w 2D TSE     | Axial       | 3970/98/150            | 3.48     | 270 × 236     | 256 × 157         | 3/0           | 13 |
| SE-DW-EPI      | Axial       | 2700/83                | 6.37     | 136 × 160     | 160 × 102         | 4/0           | /  |
| T1w FLASH 3D   | Axial       | 9.8/4.76/25            | 0.58     | 330 × 247     | 256 × 192         | 3/0           | /  |
| T1w FLASH 3D   | Axial       | 9.8/4.76/25 × 10       | 0.58     | 330 × 247     | 256 × 192         | 3/0           | /  |
| T1w 2D TSE     | Sagittal    | 538/13/150             | 2.35     | 250 × 250     | 256 × 230         | 3/0           | 5  |
| T1w 2D TSE     | Coronal     | 538/13/150             | 2.52     | 250 × 250     | 256 × 230         | 3/0           | 5  |
| T1w 2D TSE     | Axial       | 450/12/150             | 2.31     | 270 × 236     | 256 × 202         | 3/0           | 5  |

Note: TR = repetition time, TE = echo time, FOV = field of view, FA = flip angle, ST = slice thickness, TF = turbo factor, and AT = acquisition time.
A $p$ value $< 0.05$ was considered significant for all tests. All analyses were performed using Statistics Toolbox of Matlab R2007a (The Math-Works Inc., Natick, MA).

3. Results

Histopathologic analysis of the surgical specimen yielded the following findings: 5 patients had T0, 6 had T1, 14 had T2, 3 had T3, and 1 had T4 tumor. Five patients had TRG 1, 9 patients had TRG 2, 7 patients had TRG 3, and 8 patients had TRG 4.

Table 2 shows patient characteristics and volume changes assessed by the three volumetric methods: T2-w volumetric change, DCE-MRI volumetric change and DW-MRI volumetric change. Table 3 shows median and standard deviation values of volumes assessed by tree volumetric approaches before and after treatment. Wilcoxon's test findings reported significant decreases in volumetric measures, between pre- and posttreatment, assessed with all methods (Table 3): $V(C)$ median value decreased from 36.9 cm$^3$ to 16.7 cm$^3$; $V(DCE)$ median value decreased from 30.9 cm$^3$ to 16.5 cm$^3$; $V(DWI)$ median value decreased from 14.5 cm$^3$ to 6.0 cm$^3$ ($p < 0.01$).

Statistically significant differences between responders and not responders, in the volumetric percentage changes were obtained by Mann-Whitney test for all volumetric approaches (Table 3) and these were visualized in boxplots (Figure 1). Table 4 reports the performance of three volumetric methods in terms of sensitivity, specificity, and area under ROC. Optimal cut-off values were also reported. The results are statistically significant (Fisher test $p < 0.01$).

According to TRG, DCE-MRI volume estimations change after pCRT showed best results in terms of specificity, sensitivity, and accuracy, respectively, of 86%, 93%, and 93%. $V(C)$ showed a significant correlation between response and TRG with a sensitivity, a specificity and an accuracy, respectively, of 86%, 73%, and 79% (37% cut-off, AUC 0.76), and $V(DWI)$ showed a sensitivity, a specificity and an accuracy, respectively, of 64%, 94%, and 76% (39% cut-off, AUC 0.81). Figure 2 shows ROCs for three volumetric approaches. AUC of $V(DCE)$ change is superior of AUCs of $V(C)$ change and $V(DWI)$ change resulting an increase of 15.6% and of 11.1%, respectively.

Interobserver agreement was 0.977 (95% confidence interval (CI) 0.954–0.989), 0.864 (95% CI 0.835–0.884), and 0.756 (95% CI 0.705–0.780) for $V(C)$, $V(DCE)$, and $V(DWI)$.

4. Discussion

4.1. Synopsis of New Findings. The focus of this study was to clarify the association between manual tumor volume estimations obtained by T2-weighted imaging, DWI, DCE-MRI images, and TRG to predict LARC response after pCRT. This study shows that manual tumor volume estimation using DCE-MRI can furnish better performance in terms of sensitivity, specificity, and accuracy. To the best of our knowledge, no prior studies have compared the performances of manual tumor volume measurements on T2-weighted (T2-w), DWI, and DCE-MRI images to predict LARC response after pCRT.

4.2. Comparisons with Other Studies. Tumor volume has been proven to be an important prognostic indicator for a variety of tumors, although the extra workload necessary to perform manual tumor volume measurements on MRI images have limited its applications in clinical routine. The goal to be achieved after pCRT for LARC is pathologic complete response. The latter could be assessed using the TRG, a pathologic score widely considered as a potential tool to guide therapy in patients with LARC being an independent predictor of the likelihood of local recurrence, distant metastasis, and overall and disease-free survival [5]. Many approaches using MRI have been investigated to compare response after pCRT with TRG. The correlation shown between MR tumor volume estimation on T2-w images and the pCR has been the subject of many reports.

| Patient number | Age | pT | pN | TRG | $V(C)$ change [%] | $V(DCE)$ change [%] | $V(DWI)$ change [%] |
|----------------|-----|----|----|-----|-------------------|-------------------|-------------------|
| 1              | 74  | 2  | 0  | 4   | 37.00             | 33.28             | 38.86             |
| 2              | 50  | 1  | 0  | 2   | 70.76             | 91.34             | 61.08             |
| 3              | 75  | 1  | 0  | 3   | −96.50            | 29.88             | 36.67             |
| 4              | 54  | 1  | 0  | 2   | 61.22             | 67.40             | −5.60             |
| 5              | 50  | 2  | 0  | 2   | 77.65             | 35.07             | 81.40             |
| 6              | 58  | 0  | 0  | 1   | 52.36             | 46.52             | 7.69              |
| 7              | 57  | 1  | 0  | 3   | 53.18             | −3.71             | 62.42             |
| 8              | 67  | 0  | 0  | 1   | 80.34             | 70.57             | 72.33             |
| 9              | 70  | 1  | 1  | 2   | 59.99             | 39.59             | 46.72             |
| 10             | 75  | 2  | 0  | 2   | 77.81             | 78.21             | 22.49             |
| 11             | 78  | 2  | 1  | 3   | 8.85              | −38.50            | 1.51              |
| 12             | 68  | 2  | 0  | 3   | 20.20             | 27.42             | 18.58             |
| 13             | 48  | 0  | 0  | 1   | 92.84             | 86.56             | 92.89             |
| 14             | 44  | 2  | 1  | 3   | 2.37              | 21.72             | 3.00              |
| 15             | 59  | 4  | 0  | 4   | 94.93             | 8.51              | 24.50             |
| 16             | 60  | 1  | 0  | 2   | −4.52             | 28.52             | 39.50             |
| 17             | 63  | 2  | 0  | 3   | 21.73             | 13.52             | −86.38            |
| 18             | 58  | 2  | 0  | 4   | 35.39             | −2.57             | 43.52             |
| 19             | 44  | 2  | 0  | 4   | 66.01             | 34.08             | 22.63             |
| 20             | 63  | 3  | 1  | 4   | 28.05             | 3.26              | −77.05            |
| 21             | 69  | 2  | 1  | 2   | 48.51             | 44.32             | 64.58             |
| 22             | 76  | 2  | 1  | 2   | 42.17             | 68.19             | 25.73             |
| 23             | 72  | 0  | 0  | 1   | 85.58             | 79.34             | 84.50             |
| 24             | 61  | 2  | 0  | 4   | 14.12             | −83.35            | −45.41            |
| 25             | 64  | 3  | 1  | 4   | −45.75            | 20.64             | 21.25             |
| 26             | 58  | 3  | 0  | 3   | 44.51             | 18.94             | 28.28             |
| 27             | 76  | 2  | 0  | 2   | 50.72             | 60.61             | 36.40             |
| 28             | 77  | 2  | 0  | 4   | 13.16             | 75.04             | −16.52            |
| 29             | 57  | 0  | 1  | 1   | −23.73            | 12.45             | 49.65             |

Note: $pT =$ pathological T stage; $pN =$ pathological N stage; $V(C) =$ conventional T2-weighted volumetry; $V(DCE) =$ diffusion-weighted imaging volumetry; $V(DWI) =$ dynamic contrast enhanced volumetry.
parameters to increase their accuracy for tumor response be utilized in association with functional quantitative MRI microvessel density [7–9, 26]. Volumetric measure could the vascular endothelial growth factor expression and the expressed by highly vascularized tumoral tissues, such as MRI has been observed as correlated with some biomarkers Moreover, this kinetic behavior of contrast agent in DCE-a rapid gadolinium uptake, an early wash-out and overall shorter first pass, especially if compared with healthy tissues. neoformed tumor capillaries, being leaky, can determine a rapid gadolinium uptake, an early wash-out and overall shorter first pass. DW-MRI is an alternative technique potentially able to overcome part of [20] showed a significant association with pCR for patients with a tumor volume reduction rate of more than 75%, whilst Kim et al. [21] observed no significant difference with a tumor volume reduction rate of more than 75%, being capable of showing viable neoplastic tissue due to its reliability in detecting the restricted proton diffusion in hypercellular tissues with high nucleocytoplasmic ratio. According to some authors, the volume measurements obtained on post-CRT DW MR images were significantly more accurate than those obtained on post-CRT T2-w MR images to assess pathological complete response [22–25]. DCE-MRI is another technique that can provide functional information on tumor viability deriving tumoral neoangiogenic changes linked to contrast medium kinetics. Many authors described its potential advantages in predict response to therapy in different tumors [5–7], where neoformed tumor capillaries, being leaky, can determine a rapid gadolinium uptake, an early wash-out and overall shorter first pass, especially if compared with healthy tissues. Moreover, this kinetic behavior of contrast agent in DCE-MRI has been observed as correlated with some biomarkers expressed by highly vascularized tumoral tissues, such as the vascular endothelial growth factor expression and the microvessel density [7–9, 26]. Volumetric measure could be utilized in association with functional quantitative MRI parameters to increase their accuracy for tumor response treatment. In fact, a recent study of Bajpai et al. [27] reported that apparent diffusion coefficient obtained on DW-MRI did not correlate with necrosis after chemotherapy in osteosarcoma but on adjusting for volume (apparent diffusion coefficient per unit volume); significant correlation was found and this appears to be a sensitive substitute for response evaluation in osteosarcoma. Future investigations could be done using these recent findings.

However, few authors have proposed a tumor volume estimation based on DCE-MRI images, using a manual or an automatic segmentation, mainly focusing their works on breast cancer [27, 28]. Moreover, to the best of our knowledge, no study has investigated the association between these volumes measured by DCE-MRI and TRG in LARC.

4.3. Study Limitations. V(C) showed a significant correlation between response and TRG with a sensitivity, a specificity and an accuracy, respectively, of 86%, 73%, and 79% (37% cut-off, AUC 0.76). Despite the excellent agreement between observers (0.977), understaging was present in 5 patients in which were assessed a decrease in volume >38% and a TRG of 3 or 4, confirming that T2-w volume assessment alone is not sufficiently accurate, being not able to identify between the persistence of viable tissue and the peritumoral fibrosis present after radiation therapy. Moreover, according to observers, was difficult to decide which fibrotic areas, remaining suspicious for tumor on T2-w images, should be included in the volume measurements and which should not.

### Table 3: Volume measures assessed by the three volumetric methods (V(C), V(DCE), and V(DWI)).

| Tool       | All (n = 29)     | Responders (n = 14) | Nonresponders (n = 15) | p value |
|------------|------------------|---------------------|------------------------|---------|
| V(C)       |                  |                     |                        |         |
| Pre-CRT [cm³] | 36.9 ± 34.4      | 30.6 ± 22.6         | 38.4 ± 26.6            |         |
| Post-CRT [cm³] | 16.7 ± 8.8       | 12.4 ± 6.9          | 20.6 ± 9.5             |         |
| Volume change [%] | 44.5 ± 43.0    | 60.6 ± 33.2         | 21.7 ± 46.6            | <0.001* |
| V(DCE)     |                  |                     |                        |         |
| Pre-CRT [cm³] | 30.9 ± 29.1      | 31.4 ± 23.7         | 33.9 ± 25.4            |         |
| Post-CRT [cm³] | 18.5 ± 8.1       | 11.1 ± 6.7          | 24.7 ± 10.8            | <0.001* |
| Volume change [%] | 33.3 ± 38.4    | 64.0 ± 23.7         | 19.0 ± 36.9            |         |
| V(DWI)     |                  |                     |                        |         |
| Pre-CRT [cm³] | 14.6 ± 12.6      | 12.5 ± 10.1         | 15.8 ± 9.3             |         |
| Post-CRT [cm³] | 9.0 ± 5.1        | 6.4 ± 4.4           | 7.9 ± 5.5              |         |
| Volume change [%] | 28.3 ± 43.1    | 48.2 ± 30.0         | 21.2 ± 44.0            | <0.001* |

Note: results are expressed as median value ± standard deviation.

* Wilcoxon signed-rank test.

CRT, chemoradiation therapy; V(C), conventional T2-weighted volumetry; V(DWI), diffusion-weighted imaging volumetry; V(DCE), dynamic contrast enhanced volumetry.

### Table 4: Performance of volumetric approaches (V(C), V(DCE), and V(DWI)).

|                  | Sensitivity [%] | Specificity [%] | Accuracy [%] | Cut-off [%] | AUC   |
|------------------|----------------|----------------|--------------|------------|-------|
| V(C) change      | 0.86           | 0.73           | 0.79         | 37.4       | 0.76  |
| V(DCE) change    | 0.86           | 0.93           | 0.93         | 34.2       | 0.90  |
| V(DWI) change    | 0.64           | 0.94           | 0.76         | 39.1       | 0.81  |

Note: V(C), conventional T2-weighted volumetry; V(DWI), diffusion-weighted imaging volumetry; V(DCE), dynamic contrast enhanced volumetry; AUC, area under ROC.
Figure 1: Boxplots of three volumetric approaches: (a) shows $V(C)$ boxplot, (b) shows $V(DCE)$ boxplot, and (c) shows $V(DWI)$ boxplot. The middle line is the median value. The inferior and superior extremes of the box correspond to the first and third quartiles, respectively. The whiskers lines correspond to values within 1.5 times the interquartile range from the ends of the box. Outlier data beyond the ends of the whiskers are displayed with a + sign.

Figure 2: ROCs of three volumetric approaches ($V(C)$, $V(DCE)$, and $V(DWI)$).

$V(DWI)$ showed a sensitivity, a specificity, and an accuracy, respectively, of 64%, 94%, and 76% (39% cut-off, AUC 0.81) confirming the ability of $V(DWI)$ in reducing the understaging observed with $V(C)$ estimations. The agreement between observers was good (0.756) and both observers during segmentation easily and quickly recognized high-SI areas of “viable tumor” thus avoiding the inclusion of fibrotic areas that, due to their poor water content coupled with lower nucleocytoplasmic ratio, were not visible on either high $b$-value images and ADC maps. However, the low sensitivity of 64% obtained in our series reflects some intrinsic limits of $V(DWI)$ measurements: during evaluation it is mandatory to remember that small bleedings or friable haemorrhagic/necrotic tissues can impact negatively on DW evaluations, causing field inhomogeneity due to susceptibility artefacts that, causing “enlargement” and “distortion” of “bright” areas on $b$-800 images, can make the tumor segmentation not accurate; the low spatial resolution with relative...
“small voxels” obtained, despite the large Field of View (FOV) used, can be a source of wide differences in estimated volumes causing tumor overestimation on post-CRT scans. Moreover, to reduce potential sources of false negative due to overestimation of residual tumor, a comparative evaluation with ADC maps is mandatory when areas of necrosis are identified and can be wrongly included in tumor being recognised like bright areas on images acquired with high b-values (≥b-800) due to the “T2 shine effect” [29]. V(DCE) showed best results with a sensitivity, a specificity, and an accuracy, respectively, of 86%, 93%, and 93% (34% cut-off, AUC 0.90) coupled with an excellent agreement between observers (0.864). Under staging, only in 1 patient was present that, although showing a great decrease in volume >37% on pCRT scan (75%), showed a TRG of 4. This false negative was probably due to the tumor appearance, which was mainly vegetant, with a great decrease in volume on V(DCE) measurements particularly on lumen side, whilst the persisting extramural viable tumor tissue was more easily detectable on T2-w and DW scans (as large spiculae in mesorectal fat-pad or high intensity areas on b-800 images). Only 2 patients were false positive: these patients constituted the main limit of V(DCE) segmentation. The choice of segmenting tumor on subtracted images obtained after 140s from contrast agent administration leaded to an inclusion of those areas in which inflammation phenomena were prominent (areas characterized by a continuous rise in SI followed by a stable intensity over the time) with an intrinsic potential overestimation, mainly on after pCRT scans. However, being V(DCE) focussed to identify “not effective” neoadjuvant treatments a false positive could be more tolerated than a false negative.

4.4. Clinical Applicability of the Study. Despite interesting results in terms of overall performance of V(DCE), currently, standard methods for tumor volume assessment based on manual delineation of volumes are time consuming. The mean time required to perform a volume measurement using multiple ROIs was approximately 10–15 minutes when pre-and post-CRT scans were considered and experienced radiologists employed, which is impractical. Therefore, semi-automated segmentation is needed.

5. Conclusions

In literature comparative studies between DCE-MRI, DW-MRI, and conventional MR volumetry are not present to assess therapy response evaluation after pCRT in LARC. In our series, manual segmentation of tumor volumes, made on DCE-MRI subtracted images, showed the best results in terms of sensitivity, specificity, and accuracy. When these results are validated in a larger prospective study and semi-automated software will be available they could be implemented in routine practice.

Conflict of Interests

The authors declare that there is no conflict of interests regarding the publication of this paper.

References

[1] R. Siegel, D. Naishadham, and A. Jemal, “Cancer statistics, 2012,” CA Cancer Journal for Clinicians, vol. 62, no. 1, pp. 10–29, 2012.
[2] A. Avallone, P. Delrio, C. Guida et al., “Biweekly oxaliplatin, raltitrexed, 5-fluorouracil and folinic acid combination chemotherapy during preoperative radiation therapy for locally advanced rectal cancer: a phase I-II study,” British Journal of Cancer, vol. 94, no. 12, pp. 1809–1815, 2006.
[3] D. Jennings, B. N. Hatton, J. Guo et al., “Early response of prostate carcinoma xenografts to docetaxel chemotherapy monitored with diffusion MRI,” Neoplasia, vol. 4, no. 3, pp. 255–262, 2002.
[4] N. A. Janjan, C. Crane, B. W. Feig et al., “Improved overall survival among responders to preoperative chemoradiation for locally advanced rectal cancer,” American Journal of Clinical Oncology: Cancer Clinical Trials, vol. 24, no. 2, pp. 107–112, 2001.
[5] M. Maas, P. J. Nelemans, V. Valentini et al., “Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data,” The Lancet Oncology, vol. 11, no. 9, pp. 835–844, 2010.
[6] R. G. H. Beets-Tan and G. L. Beets, “Rectal cancer: review with emphasis on MR imaging,” Radiology, vol. 232, no. 2, pp. 335–346, 2004.
[7] M. O. Leach, K. M. Brindle, J. L. Evelhoch et al., “The assessment of antiangiogenic and antivascular therapies in early-stage clinical trials using magnetic resonance imaging: issues and recommendations,” British Journal of Cancer, vol. 92, no. 9, pp. 1599–1610, 2005.
[8] C. Hayes, A. R. Padhani, and M. O. Leach, “Assessing changes in tumour vascular function using dynamic contrast-enhanced magnetic resonance imaging,” NMR in Biomedicine, vol. 15, no. 2, pp. 154–163, 2002.
[9] M. Z. Xiao, D. Yu, L. Z. Hong et al., “3D dynamic contrast-enhanced MRI of rectal carcinoma at 3T: correlation with microvascular density and vascular endothelial growth factor markers of tumor angiogenesis,” Journal of Magnetic Resonance Imaging, vol. 27, no. 6, pp. 1309–1316, 2008.
[10] A. Avallone, P. Delrio, B. Pecori et al., “Oxaliplatin plus dual inhibition of thymidilate synthase during preoperative pelvic radiotherapy for locally advanced rectal carcinoma: long-term outcome,” International Journal of Radiation Oncology, Biology, Physics, vol. 79, no. 3, pp. 670–676, 2011.
[11] A. Petrillo, O. Catalano, P. Delrio et al., “Post-treatment fistulas in patients with rectal cancer: MRI with rectal superparamagnetic contrast agent,” Abdominal Imaging, vol. 32, no. 3, pp. 328–331, 2007.
[12] R. F. A. Vliegen, G. L. Beets, G. Lammering et al., “Mesorectal fascia invasion after neoadjuvant chemotherapy and radiation therapy for locally advanced rectal cancer: accuracy of MR imaging for prediction,” Radiology, vol. 246, no. 2, pp. 454–462, 2008.
[13] A.-M. Mandard, F. Dalibard, J.-C. Mandard et al., “Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma: clinicopathologic correlations,” Cancer, vol. 73, no. 11, pp. 2680–2686, 1994.
[14] C. A. M. Marijnen, I. D. Nagtegaal, E. Kapiteijn et al., “Radiotherapy does not compensate for positive resection margins in rectal cancer patients: report of a multicenter randomized trial,” International Journal of Radiation Oncology Biology Physics, vol. 55, no. 5, pp. 1311–1320, 2003.
[15] E. R. DeLong, D. M. DeLong, and D. L. Clarke-Pearson, “Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach,” *Biometrics*, vol. 44, no. 3, pp. 837–845, 1988.

[16] E. F. Schisterman, N. J. Perkins, A. Liu, and H. Bondell, “Optimal cut-point and its corresponding Youden index to discriminate individuals using pooled blood samples,” *Epidemiology*, vol. 16, no. 1, pp. 73–81, 2005.

[17] M. R. Torkzad, J. Lindholm, A. Martling, B. Cedermark, B. Glimelius, and L. Blomqvist, “MRI after preoperative radiotherapy for rectal cancer; correlation with histopathology and the role of volumetry,” *European Radiology*, vol. 17, no. 6, pp. 1566–1573, 2007.

[18] V. R. Muthusamy and K. J. Chang, “Optimal methods for staging rectal cancer,” *Clinical Cancer Research*, vol. 13, no. 22, pp. 6877–6884, 2007.

[19] MERCURY Study Group, “Diagnostic accuracy of preoperative magnetic resonance imaging in predicting curative resection of rectal cancer: prospective observational study,” *The British Medical Journal*, vol. 333, no. 7572, pp. 779–784, 2006.

[20] J. H. Kang, Y. C. Kim, H. Kim et al., “Tumor volume changes assessed by three-dimensional magnetic resonance volumetry in rectal cancer patients after preoperative chemoradiation: the impact of the volume reduction ratio on the prediction of pathological complete response,” *International Journal of Radiation Oncology Biology Physics*, vol. 76, no. 4, pp. 1018–1025, 2010.

[21] Y. H. Kim, D. Y. Kim, T. H. Kim et al., “Usefulness of magnetic resonance volumetric evaluation in predicting response to preoperative concurrent chemoradiotherapy in patients with resectable rectal cancer,” *International Journal of Radiation Oncology, Biology, Physics*, vol. 62, no. 3, pp. 761–768, 2005.

[22] L. Curvo-Semedo, D. M. J. Lambregts, M. Maas et al., “Rectal cancer: assessment of complete response to preoperative combined radiation therapy with chemotherapy—conventional MR volumetry versus diffusion-weighted MR imaging,” *Radiotherapy and Oncology*, vol. 96, no. 3, pp. 321–330, 2010.

[23] S. F. Carbone, L. Pirtoli, V. Ricci et al., “Assessment of response to chemoradiation therapy in rectal cancer using MR volumetry based on diffusion-weighted data sets: a preliminary report,” *Radiotherapy and Oncology*, vol. 117, no. 7, pp. 1112–1124, 2012.

[24] S. F. Carbone, L. Pirtoli, V. Ricci et al., “Diffusion-weighted MR volumetry for assessing the response of rectal cancer to combined radiation therapy with chemotherapy,” *Radiotherapy and Oncology*, vol. 103, no. 3, pp. 372–379, 2012.

[25] Y. C. Kim, J. S. Lim, K. C. Keum et al., “Comparison of diffusion-weighted MRI and MR volumetry in the evaluation of early treatment outcomes after preoperative chemoradiotherapy for locally advanced rectal cancer,” *Journal of Magnetic Resonance Imaging*, vol. 34, no. 3, pp. 570–576, 2011.

[26] J. Bajpai, S. Gamanagatti, M. C. Sharma et al., “Noninvasive imaging surrogate of angiogenesis in osteosarcoma,” *Pediatric Blood and Cancer*, vol. 54, no. 4, pp. 526–531, 2010.

[27] J. Bajpai, S. Gamanagatti, R. Kumar et al., “Role of MRI in osteosarcoma for evaluation and prediction of chemotherapy response: correlation with histological necrosis,” *Pediatric Radiology*, vol. 41, no. 4, pp. 441–450, 2011.

[28] A. Yi, N. Cho, S.-A. Im et al., “Survival outcomes of breast cancer patients who receive neoadjuvant chemotherapy: association with dynamic contrast-enhanced MR imaging with computer-aided evaluation,” *Radiotherapy and Oncology*, vol. 103, no. 3, pp. 662–672, 2013.

[29] Q. Liu, J.-M. Ye, L. Xu, X.-N. Duan, J.-X. Zhao, and Y.-H. Liu, “Correlation between dynamic contrast-enhanced MRI and histopathology in the measurement of tumor and breast volume and their ratio in breast cancer patients: a prospective study,” *Chinese Medical Journal*, vol. 125, no. 21, pp. 3856–3860, 2012.